Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 11/20 | 0.54 |
| ▸ | SPIN1 | Q9Y657 | 2/20 | 0.39 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17106567 | 1.00 | EHMT2 (0.54) | EHMT2SPIN1EHMT1KDM4EALDH1A1 | |
| SCHEMBL17106574 | 0.88 | EHMT2 (0.49) | EHMT2SPIN1EHMT1KDM4EALDH1A1 | |
| SCHEMBL17106556 | 0.81 | MAPT (0.36) | KDM4EALDH1A1CYP2D6L3MBTL1 | |
| SCHEMBL21667955 | 0.78 | EHMT2 (0.43) | EHMT2SPIN1EHMT1KDM4EALDH1A1 | |
| SCHEMBL17106558 | 0.76 | ALDH1A1 (0.42) | KDM4EALDH1A1CYP2D6L3MBTL1 | |
| SCHEMBL17106580 | 0.73 | KMT2A (0.47) | ALDH1A1 | |
| SCHEMBL17106581 | 0.71 | EGFR (0.40) | KDM4EALDH1A1 | |
| SCHEMBL24428933 | 0.70 | EHMT2 (1.00) | EHMT2SPIN1EHMT1 | |
| SCHEMBL17106573 | 0.70 | EHMT2 (1.00) | EHMT2SPIN1EHMT1 | |
| SCHEMBL17106569 | 0.70 | EHMT2 (1.00) | EHMT2SPIN1EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284272-B2 | Inhibitors of histone methyltransferase G9a | ABBVIE INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150274660-A1 | INHIBITORS OF HISTONE METHYLTRANSFERASE G9a | ABBVIE INC. | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274660-A1 | INHIBITORS OF HISTONE METHYLTRANSFERASE G9a | EHMT1, EHMT2, EZH2 | EHMT2 2/4885SPIN1 1994/4885EHMT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.